Banning all drug promotion is the best option pending major reforms.

被引：7
作者：
Mansfield P.R. [1 ]
机构：
[1] Department of General Practice, University of Adelaide
来源：
Journal of Bioethical Inquiry | 2005年 / 2卷 / 2期
基金：
英国医学研究理事会;
关键词：
Drug industry; advertising; public policy; ethics;
D O I：
10.1007/BF02448846
中图分类号：
学科分类号：
摘要：
Drug promotion should be evaluated according to its impact on health, access to information, informed consent, and wealth. Drug promotion currently does more harm than good to each of these objectives because it is usually misleading. This is a systemic problem. Whilst improved regulation and education will address it to some degree, major reforms to payment systems for drug companies and doctors are also required. Until all these systemic reforms can be put in place, the best policy option is to ban the promotion of drugs to doctors and the public. Consequently, pending major reforms, it is appropriate for governments to restrict drug promotion as much as is politically achievable.
引用
收藏
页码：75 / 81
页数：6
相关论文
共 38 条
[1]  
Mansfield PR(2003)Healthy Skepticism’s new AdWatch: understanding drug promotion Med J Aust 179 644-645
[2]  
Mansfield P(2004)Accepting what we can learn from advertising’s mirror of desire BMJ 329 1487-8
[3]  
Wilkes MS(1992)Pharmaceutical advertisements in leading medical journals: experts’ assessments Ann Intern Med 116 912-9
[4]  
Doblin BH(2004)Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions Med J Aust 181 524-5
[5]  
Shapiro MF(2005)Surrogate end points in clinical trials: are we being misled? Scrip World Pharmaceutical News 28 2-13
[6]  
Langton PE(1996)Dispelling the illusion of invulnerability: the motivations and mechanisms of resistance to persuasion Ann Intern Med 125 605-541
[7]  
Hankey GJ(2002)MaLAM, a medical lobby for appropriate marketing of pharmaceuticals J Pers Soc Psychol 83 526-592
[8]  
Eikelboom JW(1997)Timing of new black box warnings and withdrawals for prescription medications Med J Aust 167 590-2220
[9]  
Fleming TR(2002)Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions JAMA 287 2215-5
[10]  
DeMets DL(2004)Direct to consumer advertising policy is at the crossroads of competing pressures and health needs (editorial) Med J Aust 181 524-6
1234